A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the ...

A team of scientists, including researchers from University College London (UCL), has discovered key differences in how four ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the ...

While misfolded SOD1 proteins (among others) cause ALS, misfolded amyloid beta oligomers cause Alzheimer's disease. "These are good proteins gone bad," Klein said. "They are good proteins, but when ...

NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern ...

Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical trial of the vaccine candidate ALZ-101 in early Alzheimer's disease. This mi ...

In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD ...

Promis Neurosciences Inc. recently presented the rational design of an Alzheimer’s disease (AD) vaccine candidate maximizing the selective targeting of toxic amyloid-β oligomers.

ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today ...

A consequence of this is that toxic amyloid-beta oligomers (small clumps of amyloid-beta protein) may “sneak in” to the neurons via this same receptor. Conversely, the SN expresses a selective ...

At the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (ADPD), Promis Neurosciences Inc. presented the rational design of an Alzheimer’s ...